Novel radiolabeled ligand, Para-chloro-2-[<sup>18</sup>F]fluoroethyletomidate (CETO) compared to [<sup>11</sup>C]metomidate-PET (MTO) for the lateralisation of primary aldosteronism (PA)Emily Goodchild, Morris J. Brown, Anju Sadhev et al.|Endocrine Abstracts|2022Cited by 1
11C-metomidate PET CT versus Adrenal Vein Sampling for diagnosing surgically curable primary aldosteronism: prospective test validation, and impact of somatic genotype and ethnicity on outcomesXilin Wu, Morris J. Brown, Victoria Warnes et al.|Research Square|2021Cited by 0
Complete clinical cure of primary aldosteronism (PA) is predictable and sustained for at least two yearsEmily Goodchild, Morris J. Brown, Emmanuel Savage et al.|Endocrine Abstracts|2022Cited by 0